Dagatan, Claudio C.
HRN: 05-32-69 Sex: MalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
11/14/2023
CEFUROXIME 750MG (VIAL)
11/14/2023
11/20/2023
IVT
750mg
Q8
Sti Sec To Va
Waiting Final Action
Indication: Empiric Type of Infection: Skin & Soft Tissue Compliance to guidelines: Non-compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes